Akash Nanda

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 74:1419-23. 2009
  2. doi request reprint Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 76:1439-44. 2010
  3. doi request reprint Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, 75 Francis St, ASB1 L2, Boston, MA 02115, USA
    JAMA 302:866-73. 2009
  4. doi request reprint Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 77:147-52. 2010

Detail Information

Publications4

  1. doi request reprint Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 74:1419-23. 2009
    ..To compare prostate-specific antigen (PSA) outcomes in a cohort of men with high-risk prostate cancer based on the presence or absence of any Gleason Grade 5 component (primary, secondary, or tertiary)...
  2. doi request reprint Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 76:1439-44. 2010
    ..a luteinizing hormone-releasing hormone (LHRH) agonist alone affects the risk of prostate cancer-specific mortality (PCSM) in men with localized but high-risk disease treated with radiotherapy...
  3. doi request reprint Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, 75 Francis St, ASB1 L2, Boston, MA 02115, USA
    JAMA 302:866-73. 2009
    ..However, it is unknown which comorbid conditions eliminate this survival benefit...
  4. doi request reprint Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 77:147-52. 2010
    ....